Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Evofem's EVO100 receives Fast Track designation for prevention of gonorrhea » 09:03
05/12/21
05/12
09:03
05/12/21
09:03
EVFM

Evofem

$1.25 /

+0.04 (+3.31%)

Evofem Biosciences…

Evofem Biosciences announced that the FDA has granted Fast Track designation for EVO100 for the prevention of urogenital gonorrhea in women. Fast Track designation is designed to facilitate the development and expedite the review of new therapies to treat serious conditions and fill unmet medical needs. More than 600,000 cases of gonorrhea were reported in 2019. Currently, there are no FDA-approved prescription products to prevent gonorrhea. EVO100 previously received Fast Track designation from the FDA for the prevention of chlamydia in women and was also designated as a Qualified Infectious Disease Product by the FDA for the prevention of gonorrhea in women. A drug that receives QIDP designation may qualify for an additional five years of marketing exclusivity. Evofem's pivotal Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women, EVOGUARD, is currently enrolling 1,730 women in U.S. study sites. The company expects to complete enrollment by year-end 2021 and to report top-line data in mid-2022. Positive outcomes could support submission of a New Drug Application to the FDA for these potential indications by the end of 2022, with an anticipated PDUFA date in 3Q23 due to the expedited review afforded by the Fast Track designation.

ShowHide Related Items >><<
EVFM Evofem
$1.25 /

+0.04 (+3.31%)

EVFM Evofem
$1.25 /

+0.04 (+3.31%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
EVFM Evofem
$1.25 /

+0.04 (+3.31%)

  • 25
    Mar
  • 03
    Jun
EVFM Evofem
$1.25 /

+0.04 (+3.31%)

EVFM Evofem
$1.25 /

+0.04 (+3.31%)

Over a week ago
Earnings
Evofem reports Q1 EPS (56c), consensus (49c) » 16:08
05/06/21
05/06
16:08
05/06/21
16:08
EVFM

Evofem

$1.23 /

-0.07 (-5.38%)

Reports Q1 revenue $1.1M,…

Reports Q1 revenue $1.1M, consensus $1.63M. "Our 'Get Phexxi' DTC campaign launched nationwide on Valentine's Day, resulting in strong Q1 growth. More than 5,000 healthcare providers have prescribed Phexxi to date, and Phexxi prescriptions increased 83% from February to March," said CEO Saundra Pelletier. "Contraception is the most promotionally-sensitive pharmaceutical category, and we expect this ongoing campaign will continue to drive Phexxi uptake."

ShowHide Related Items >><<
EVFM Evofem
$1.23 /

-0.07 (-5.38%)

EVFM Evofem
$1.23 /

-0.07 (-5.38%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
EVFM Evofem
$1.23 /

-0.07 (-5.38%)

  • 25
    Mar
  • 03
    Jun
EVFM Evofem
$1.23 /

-0.07 (-5.38%)

EVFM Evofem
$1.23 /

-0.07 (-5.38%)

Options
Evofem Biosciences options imply 27.1% move in share price post-earnings » 15:34
05/06/21
05/06
15:34
05/06/21
15:34
EVFM

Evofem

$1.23 /

-0.07 (-5.38%)

Pre-earnings options…

Pre-earnings options volume in Evofem Biosciences is normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 27.1%, or 33c, after results are released. Median move over the past eight quarters is 4.1%.

ShowHide Related Items >><<
EVFM Evofem
$1.23 /

-0.07 (-5.38%)

EVFM Evofem
$1.23 /

-0.07 (-5.38%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
EVFM Evofem
$1.23 /

-0.07 (-5.38%)

  • 25
    Mar
  • 03
    Jun
EVFM Evofem
$1.23 /

-0.07 (-5.38%)

Over a month ago
On The Fly
Fly Intel: Wall Street's Top Stories for Thursday » 16:33
03/25/21
03/25
16:33
03/25/21
16:33
NKE

Nike

$128.62 /

-4.53 (-3.40%)

, HNNMY

Hennes & Mauritz

$0.00 /

+ (+0.00%)

, RAD

Rite Aid

$18.57 /

-4.765 (-20.42%)

, DRI

Darden

$144.91 /

+10.93 (+8.16%)

, IIVI

II-VI

$66.69 /

-0.68 (-1.01%)

, LITE

Lumentum

$85.74 /

+6.74 (+8.53%)

, COHR

Coherent

$257.39 /

+0.39 (+0.15%)

, AZN

AstraZeneca

$49.68 /

+0.91 (+1.87%)

, VZIO

Vizio

$19.20 /

+1.6 (+9.09%)

, CRCT

Cricut

$17.97 /

+2.07 (+13.02%)

, DSEY

Diversey

$14.85 /

+1.2401 (+9.11%)

, LVTX

Lava Therapeutics

$13.45 /

+1.23 (+10.07%)

, OLK

Olink

$36.14 /

+5.925 (+19.61%)

, APO

Apollo Global

$46.96 /

-0.71 (-1.49%)

, CERT

Certara

$28.54 /

+2.75 (+10.66%)

, CRIS

Curis

$11.80 /

+1.48 (+14.34%)

, EVFM

Evofem

$1.71 /

-0.62 (-26.67%)

, EOLS

Evolus

$12.69 /

-3.79 (-23.00%)

, MSDA

MSD Acquisition

$0.00 /

+ (+0.00%)

The major averages were…

ShowHide Related Items >><<
RAD Rite Aid
$18.57 /

-4.765 (-20.42%)

NKE Nike
$128.62 /

-4.53 (-3.40%)

LITE Lumentum
$85.74 /

+6.74 (+8.53%)

IIVI II-VI
$66.69 /

-0.68 (-1.01%)

EVFM Evofem
$1.71 /

-0.62 (-26.67%)

EOLS Evolus
$12.69 /

-3.79 (-23.00%)

DRI Darden
$144.91 /

+10.93 (+8.16%)

CRIS Curis
$11.80 /

+1.48 (+14.34%)

AZN AstraZeneca
$49.68 /

+0.91 (+1.87%)

APO Apollo Global
$46.96 /

-0.71 (-1.49%)

NKE Nike
$128.62 /

-4.53 (-3.40%)

03/26/21 Baird
Baird upgrades Nike after two years, sees concerns as temporary
03/26/21 Baird
Nike upgraded to Outperform from Neutral at Baird
03/22/21 UBS
Earnings and stock price momentum at Nike like not peaked, says UBS
03/19/21 BTIG
BTIG says Nike should make up revenue lost to supply chain issues
HNNMY Hennes & Mauritz
$0.00 /

+ (+0.00%)

03/18/21 RBC Capital
Hennes & Mauritz price target raised to SEK 240 from SEK 225 at RBC Capital
03/16/21 Barclays
Hennes & Mauritz price target raised to SEK 235 from SEK 200 at Barclays
02/03/21 Morgan Stanley
Hennes & Mauritz price target raised to SEK 95 from SEK 90 at Morgan Stanley
01/27/21 Credit Suisse
Hennes & Mauritz price target raised to SEK 155 from SEK 150 at Credit Suisse
RAD Rite Aid
$18.57 /

-4.765 (-20.42%)

03/25/21 Deutsche Bank
Rite Aid price target raised to $27 from $17 at Deutsche Bank
03/25/21 Deutsche Bank
Rite Aid named short-term buy idea at Deutsche Bank
12/18/20 Deutsche Bank
Rite Aid price target raised to $17 from $9 at Deutsche Bank
11/17/20 Oppenheimer
Amazon's Pharmacy push should continue to disrupt supply chain, says Oppenheimer
DRI Darden
$144.91 /

+10.93 (+8.16%)

03/26/21 Truist
Darden price target raised to $158 from $150 at Truist
03/26/21 UBS
Darden price target raised to $165 from $160 at UBS
03/26/21 Deutsche Bank
Darden price target raised to $145 from $124 at Deutsche Bank
03/26/21 Wedbush
Darden price target raised to $146 from $126 at Wedbush
IIVI II-VI
$66.69 /

-0.68 (-1.01%)

03/26/21 Cowen
II-VI weakness on deal announcement a buying opportunity, says Cowen
03/26/21 B. Riley
II-VI upgraded to Buy from Neutral at B. Riley Securities
03/18/21 Susquehanna
Lumentum bid for Coherent reaching risk tolerance limits, says Susquehanna
02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
LITE Lumentum
$85.74 /

+6.74 (+8.53%)

03/26/21 Raymond James
Lumentum upgraded to Strong Buy from Outperform at Raymond James
03/18/21
Fly Intel: Top five analyst downgrades
COHR Coherent
$257.39 /

+0.39 (+0.15%)

AZN AstraZeneca
$49.68 /

+0.91 (+1.87%)

03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 Jefferies
AstraZeneca upgraded to Buy from Hold at Jefferies
VZIO Vizio
$19.20 /

+1.6 (+9.09%)

CRCT Cricut
$17.97 /

+2.07 (+13.02%)

DSEY Diversey
$14.85 /

+1.2401 (+9.11%)

LVTX Lava Therapeutics
$13.45 /

+1.23 (+10.07%)

OLK Olink
$36.14 /

+5.925 (+19.61%)

APO Apollo Global
$46.96 /

-0.71 (-1.49%)

03/23/21
Fly Intel: Top five analyst upgrades
03/22/21 Citi
Apollo Global upgraded to Buy at Citi on 'favorable' governance changes
03/22/21 Citi
Apollo Global upgraded to Buy from Neutral at Citi
03/09/21 BMO Capital
Apollo Global price target raised to $70 from $58 at BMO Capital
CERT Certara
$28.54 /

+2.75 (+10.66%)

03/02/21 Barclays
Certara initiated with an Overweight at Barclays
03/02/21 Barclays
Certara initiated with an Overweight at Barclays
01/05/21 Morgan Stanley
Morgan Stanley starts Certara at Equal Weight, says fully valued
01/05/21 Morgan Stanley
Certara initiated with an Equal Weight at Morgan Stanley
CRIS Curis
$11.80 /

+1.48 (+14.34%)

03/25/21 B. Riley
Curis initiated with a Buy at B. Riley Securities
03/17/21 JonesTrading
Curis price target raised to $18 from $14 at JonesTrading
01/15/21 H.C. Wainwright
Curis price target raised to $16 from $9 at H.C. Wainwright
12/16/20 Cantor Fitzgerald
Curis price target raised to $15 from $4 at Cantor Fitzgerald
EVFM Evofem
$1.71 /

-0.62 (-26.67%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
EOLS Evolus
$12.69 /

-3.79 (-23.00%)

03/24/21 H.C. Wainwright
Evolus price target raised to $20 from $18 at H.C. Wainwright
02/24/21 Truist
Evolus downgraded to Hold from Buy at Truist
02/24/21 Truist
Evolus downgraded to Hold from Buy at Truist
02/22/21 Barclays
Evolus price target raised to $8 from $4 at Barclays
MSDA MSD Acquisition
$0.00 /

+ (+0.00%)

RAD Rite Aid
$18.57 /

-4.765 (-20.42%)

NKE Nike
$128.62 /

-4.53 (-3.40%)

LITE Lumentum
$85.74 /

+6.74 (+8.53%)

IIVI II-VI
$66.69 /

-0.68 (-1.01%)

EVFM Evofem
$1.71 /

-0.62 (-26.67%)

EOLS Evolus
$12.69 /

-3.79 (-23.00%)

DRI Darden
$144.91 /

+10.93 (+8.16%)

CRIS Curis
$11.80 /

+1.48 (+14.34%)

COHR Coherent
$257.39 /

+0.39 (+0.15%)

CERT Certara
$28.54 /

+2.75 (+10.66%)

AZN AstraZeneca
$49.68 /

+0.91 (+1.87%)

APO Apollo Global
$46.96 /

-0.71 (-1.49%)

  • 25
    Mar
  • 25
    Mar
  • 25
    Mar
  • 25
    Mar
  • 25
    Mar
  • 25
    Mar
  • 25
    Mar
  • 09
    Dec
  • 11
    Dec
  • 02
    Jul
  • 03
    Jun
  • 21
    Apr
NKE Nike
$128.62 /

-4.53 (-3.40%)

LITE Lumentum
$85.74 /

+6.74 (+8.53%)

IIVI II-VI
$66.69 /

-0.68 (-1.01%)

EOLS Evolus
$12.69 /

-3.79 (-23.00%)

AZN AstraZeneca
$49.68 /

+0.91 (+1.87%)

APO Apollo Global
$46.96 /

-0.71 (-1.49%)

VZIO Vizio
$19.20 /

+1.6 (+9.09%)

RAD Rite Aid
$18.57 /

-4.765 (-20.42%)

NKE Nike
$128.62 /

-4.53 (-3.40%)

IIVI II-VI
$66.69 /

-0.68 (-1.01%)

EOLS Evolus
$12.69 /

-3.79 (-23.00%)

DRI Darden
$144.91 /

+10.93 (+8.16%)

CRIS Curis
$11.80 /

+1.48 (+14.34%)

CRCT Cricut
$17.97 /

+2.07 (+13.02%)

CERT Certara
$28.54 /

+2.75 (+10.66%)

AZN AstraZeneca
$49.68 /

+0.91 (+1.87%)

APO Apollo Global
$46.96 /

-0.71 (-1.49%)

RAD Rite Aid
$18.57 /

-4.765 (-20.42%)

NKE Nike
$128.62 /

-4.53 (-3.40%)

LITE Lumentum
$85.74 /

+6.74 (+8.53%)

EVFM Evofem
$1.71 /

-0.62 (-26.67%)

EOLS Evolus
$12.69 /

-3.79 (-23.00%)

DRI Darden
$144.91 /

+10.93 (+8.16%)

CRIS Curis
$11.80 /

+1.48 (+14.34%)

CERT Certara
$28.54 /

+2.75 (+10.66%)

AZN AstraZeneca
$49.68 /

+0.91 (+1.87%)

APO Apollo Global
$46.96 /

-0.71 (-1.49%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:26
03/25/21
03/25
12:26
03/25/21
12:26
NKE

Nike

$127.16 /

-5.99 (-4.50%)

, AZN

AstraZeneca

$49.31 /

+0.54 (+1.11%)

, IIVI

II-VI

$66.73 /

-0.64 (-0.95%)

, COHR

Coherent

$255.75 /

-1.25 (-0.49%)

, LITE

Lumentum

$85.36 /

+6.36 (+8.05%)

, CERT

Certara

$27.90 /

+2.11 (+8.18%)

, CRIS

Curis

$11.40 /

+1.08 (+10.47%)

, EVFM

Evofem

$1.77 /

-0.56 (-24.09%)

, EOLS

Evolus

$13.14 /

-3.34 (-20.27%)

The major averages are…

ShowHide Related Items >><<
NKE Nike
$127.16 /

-5.99 (-4.50%)

LITE Lumentum
$85.36 /

+6.36 (+8.05%)

IIVI II-VI
$66.73 /

-0.64 (-0.95%)

EVFM Evofem
$1.77 /

-0.56 (-24.09%)

EOLS Evolus
$13.14 /

-3.34 (-20.27%)

CRIS Curis
$11.40 /

+1.08 (+10.47%)

AZN AstraZeneca
$49.31 /

+0.54 (+1.11%)

NKE Nike
$127.16 /

-5.99 (-4.50%)

03/22/21 UBS
Earnings and stock price momentum at Nike like not peaked, says UBS
03/19/21 BTIG
BTIG says Nike should make up revenue lost to supply chain issues
03/19/21 UBS
UBS sees upside in Nike guidance, keeps Buy rating after Q3 results
03/19/21 Citi
Nike brand 'strong as ever' despite Q3 sales miss, says Citi
AZN AstraZeneca
$49.31 /

+0.54 (+1.11%)

03/23/21 Societe Generale
AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Societe Generale
03/18/21 Deutsche Bank
AstraZeneca price target raised to 10,200 GBp from 10,000 GBp at Deutsche Bank
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 Jefferies
AstraZeneca upgraded to Buy from Hold at Jefferies
IIVI II-VI
$66.73 /

-0.64 (-0.95%)

03/18/21 Susquehanna
Lumentum bid for Coherent reaching risk tolerance limits, says Susquehanna
02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
COHR Coherent
$255.75 /

-1.25 (-0.49%)

03/18/21 Rosenblatt
Lumentum downgraded to Neutral on Apple headwinds at Rosenblatt
02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
LITE Lumentum
$85.36 /

+6.36 (+8.05%)

03/18/21
Fly Intel: Top five analyst downgrades
03/18/21 Rosenblatt
Lumentum downgraded to Neutral from Buy at Rosenblatt
CERT Certara
$27.90 /

+2.11 (+8.18%)

03/02/21 Barclays
Certara initiated with an Overweight at Barclays
03/02/21 Barclays
Certara initiated with an Overweight at Barclays
01/05/21 Morgan Stanley
Morgan Stanley starts Certara at Equal Weight, says fully valued
01/05/21 Morgan Stanley
Certara initiated with an Equal Weight at Morgan Stanley
CRIS Curis
$11.40 /

+1.08 (+10.47%)

03/25/21 B. Riley
Curis initiated with a Buy at B. Riley Securities
03/17/21 JonesTrading
Curis price target raised to $18 from $14 at JonesTrading
01/15/21 H.C. Wainwright
Curis price target raised to $16 from $9 at H.C. Wainwright
12/16/20 Cantor Fitzgerald
Curis price target raised to $15 from $4 at Cantor Fitzgerald
EVFM Evofem
$1.77 /

-0.56 (-24.09%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
EOLS Evolus
$13.14 /

-3.34 (-20.27%)

03/24/21 H.C. Wainwright
Evolus price target raised to $20 from $18 at H.C. Wainwright
02/24/21 Truist
Evolus downgraded to Hold from Buy at Truist
02/24/21 Truist
Evolus downgraded to Hold from Buy at Truist
02/22/21 Barclays
Evolus price target raised to $8 from $4 at Barclays
NKE Nike
$127.16 /

-5.99 (-4.50%)

LITE Lumentum
$85.36 /

+6.36 (+8.05%)

IIVI II-VI
$66.73 /

-0.64 (-0.95%)

EVFM Evofem
$1.77 /

-0.56 (-24.09%)

EOLS Evolus
$13.14 /

-3.34 (-20.27%)

CRIS Curis
$11.40 /

+1.08 (+10.47%)

COHR Coherent
$255.75 /

-1.25 (-0.49%)

CERT Certara
$27.90 /

+2.11 (+8.18%)

AZN AstraZeneca
$49.31 /

+0.54 (+1.11%)

  • 25
    Mar
  • 25
    Mar
  • 09
    Dec
  • 11
    Dec
  • 02
    Jul
  • 03
    Jun
NKE Nike
$127.16 /

-5.99 (-4.50%)

IIVI II-VI
$66.73 /

-0.64 (-0.95%)

EOLS Evolus
$13.14 /

-3.34 (-20.27%)

COHR Coherent
$255.75 /

-1.25 (-0.49%)

AZN AstraZeneca
$49.31 /

+0.54 (+1.11%)

NKE Nike
$127.16 /

-5.99 (-4.50%)

IIVI II-VI
$66.73 /

-0.64 (-0.95%)

EVFM Evofem
$1.77 /

-0.56 (-24.09%)

EOLS Evolus
$13.14 /

-3.34 (-20.27%)

CRIS Curis
$11.40 /

+1.08 (+10.47%)

COHR Coherent
$255.75 /

-1.25 (-0.49%)

CERT Certara
$27.90 /

+2.11 (+8.18%)

AZN AstraZeneca
$49.31 /

+0.54 (+1.11%)

NKE Nike
$127.16 /

-5.99 (-4.50%)

LITE Lumentum
$85.36 /

+6.36 (+8.05%)

EVFM Evofem
$1.77 /

-0.56 (-24.09%)

EOLS Evolus
$13.14 /

-3.34 (-20.27%)

CRIS Curis
$11.40 /

+1.08 (+10.47%)

CERT Certara
$27.90 /

+2.11 (+8.18%)

AZN AstraZeneca
$49.31 /

+0.54 (+1.11%)

On The Fly
Fly Intel: Pre-market Movers » 08:55
03/25/21
03/25
08:55
03/25/21
08:55
LITE

Lumentum

$79.04 /

-3.45 (-4.18%)

, ENOB

Enochian Biosciences

$3.51 /

-0.25 (-6.65%)

, SYBX

Synlogic

$3.84 /

-0.26 (-6.34%)

, AMWL

Amwell

$18.59 /

-0.41 (-2.16%)

, DRI

Darden

$133.77 /

-2.98 (-2.18%)

, MOV

Movado

$21.62 /

-0.69 (-3.09%)

, RH

RH

$486.00 /

-20.61 (-4.07%)

, IIVI

II-VI

$67.32 /

+1.39 (+2.11%)

, RAD

Rite Aid

$23.33 /

-0.42 (-1.77%)

, EVFM

Evofem

$2.33 /

-0.245 (-9.53%)

, COHR

Coherent

$257.00 /

-2 (-0.77%)

Check out this morning's…

ShowHide Related Items >><<
SYBX Synlogic
$3.84 /

-0.26 (-6.34%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

MOV Movado
$21.62 /

-0.69 (-3.09%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

ENOB Enochian Biosciences
$3.51 /

-0.25 (-6.65%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

03/18/21
Fly Intel: Top five analyst downgrades
03/18/21 Susquehanna
Lumentum bid for Coherent reaching risk tolerance limits, says Susquehanna
03/18/21 Rosenblatt
Lumentum downgraded to Neutral on Apple headwinds at Rosenblatt
03/18/21 Rosenblatt
Lumentum downgraded to Neutral from Buy at Rosenblatt
ENOB Enochian Biosciences
$3.51 /

-0.25 (-6.65%)

SYBX Synlogic
$3.84 /

-0.26 (-6.34%)

03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
AMWL Amwell
$18.59 /

-0.41 (-2.16%)

03/25/21 Cowen
Amwell price target lowered to $35 from $41 at Cowen
03/25/21 Piper Sandler
Amwell price target lowered to $30 from $45 at Piper Sandler
03/23/21 Piper Sandler
Piper remains buyer of telehealth companies despite Amazon competition
03/17/21 Stephens
Amazon news latest sign of rising telehealth competition, says Stephens
DRI Darden
$133.77 /

-2.98 (-2.18%)

03/23/21 RBC Capital
Darden price target raised to $151 from $138 at RBC Capital
03/22/21 Raymond James
Darden price target raised to $155 from $137.50 at Raymond James
03/19/21 Barclays
Darden price target raised to $145 from $131 at Barclays
03/18/21 Wells Fargo
Darden price target raised to $160 from $140 at Wells Fargo
MOV Movado
$21.62 /

-0.69 (-3.09%)

RH RH
$486.00 /

-20.61 (-4.07%)

03/25/21 Wedbush
RH price target raised to $550 from $520 at Wedbush
03/25/21 Wells Fargo
RH price target raised to $575 from $525 at Wells Fargo
03/25/21 Loop Capital
RH price target raised to $600 from $520 at Loop Capital
03/25/21 Cowen
RH price target raised to $600 from $570 at Cowen
IIVI II-VI
$67.32 /

+1.39 (+2.11%)

02/12/21 Benchmark
Benchmark maintains Buy rating on II-VI after Coherent bid
02/10/21 DA Davidson
II-VI price target raised to $115 from $60 at DA Davidson
02/10/21 Cowen
II-VI price target raised to $124 from $86 at Cowen
RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

03/25/21 Deutsche Bank
Rite Aid price target raised to $27 from $17 at Deutsche Bank
03/25/21 Deutsche Bank
Rite Aid named short-term buy idea at Deutsche Bank
12/18/20 Deutsche Bank
Rite Aid price target raised to $17 from $9 at Deutsche Bank
11/17/20 Oppenheimer
Amazon's Pharmacy push should continue to disrupt supply chain, says Oppenheimer
EVFM Evofem
$2.33 /

-0.245 (-9.53%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
COHR Coherent
$257.00 /

-2 (-0.77%)

02/11/21 Benchmark
Coherent downgraded to Hold from Buy at Benchmark
SYBX Synlogic
$3.84 /

-0.26 (-6.34%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

MOV Movado
$21.62 /

-0.69 (-3.09%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

COHR Coherent
$257.00 /

-2 (-0.77%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

  • 25
    Mar
  • 15
    Jan
  • 17
    Sep
  • 02
    Jul
  • 03
    Jun
  • 21
    Apr
LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

IIVI II-VI
$67.32 /

+1.39 (+2.11%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

LITE Lumentum
$79.04 /

-3.45 (-4.18%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

DRI Darden
$133.77 /

-2.98 (-2.18%)

AMWL Amwell
$18.59 /

-0.41 (-2.16%)

Syndicate
Evofem 17.143M share Spot Secondary priced at $1.75 » 05:30
03/25/21
03/25
05:30
03/25/21
05:30
EVFM

Evofem

$2.33 /

-0.245 (-9.53%)

Morgan Stanley and Stifel…

Morgan Stanley and Stifel acted as joint book running managers for the offering.

ShowHide Related Items >><<
EVFM Evofem
$2.33 /

-0.245 (-9.53%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
EVFM Evofem
$2.33 /

-0.245 (-9.53%)

  • 25
    Mar
  • 03
    Jun
EVFM Evofem
$2.33 /

-0.245 (-9.53%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

On The Fly
Fly Intel: After-Hours Movers » 18:45
03/24/21
03/24
18:45
03/24/21
18:45
RH

RH

$486.00 /

-20.61 (-4.07%)

, FUL

H.B. Fuller

$58.89 /

+0.68 (+1.17%)

, JEF

Jefferies Financial Group

$32.53 /

-0.34 (-1.03%)

, TCDA

Tricida

$4.73 /

-0.29 (-5.78%)

, RAD

Rite Aid

$23.33 /

-0.42 (-1.77%)

, EOLS

Evolus

$16.48 /

+0.38 (+2.36%)

, KBH

KB Home

$43.49 /

+0.12 (+0.28%)

, EVFM

Evofem

$2.33 /

-0.245 (-9.53%)

, FLL

Full House Resorts

$6.70 /

-0.35 (-4.96%)

Check out this evening's…

ShowHide Related Items >><<
TCDA Tricida
$4.73 /

-0.29 (-5.78%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

KBH KB Home
$43.49 /

+0.12 (+0.28%)

JEF Jefferies Financial Group
$32.53 /

-0.34 (-1.03%)

FUL H.B. Fuller
$58.89 /

+0.68 (+1.17%)

FLL Full House Resorts
$6.70 /

-0.35 (-4.96%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

EOLS Evolus
$16.48 /

+0.38 (+2.36%)

RH RH
$486.00 /

-20.61 (-4.07%)

03/19/21 JPMorgan
RH price target raised to $570 from $550 at JPMorgan
03/09/21 Citi
Citi starts Best Buy with Sell, sees 'too many red flags'
03/08/21 Citi
RH initiated with a Buy at Citi
02/17/21 Cowen
RH price target raised to $570 from $520 at Cowen
FUL H.B. Fuller
$58.89 /

+0.68 (+1.17%)

01/27/21 Deutsche Bank
H.B. Fuller price target raised to $56 from $48 at Deutsche Bank
01/04/21 Baird
H.B. Fuller upgraded to Outperform, added to 2021 top picks at Baird
01/04/21 Baird
H.B. Fuller upgraded to Outperform from Neutral at Baird
12/18/20
Fly Intel: Top five analyst upgrades
JEF Jefferies Financial Group
$32.53 /

-0.34 (-1.03%)

01/06/21 Oppenheimer
Jefferies Financial Group price target raised to $32 from $26 at Oppenheimer
01/05/21 Wells Fargo
Goldman Sachs shares to pass all-time high 'soon,' says Wells Fargo
09/16/20 Keefe Bruyette
Jefferies upgraded to Outperform from Market Perform at Keefe Bruyette
TCDA Tricida
$4.73 /

-0.29 (-5.78%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

12/18/20 Deutsche Bank
Rite Aid price target raised to $17 from $9 at Deutsche Bank
11/17/20 Oppenheimer
Amazon's Pharmacy push should continue to disrupt supply chain, says Oppenheimer
11/17/20 Goldman Sachs
Goldman says Amazon news likely to pressure entire pharmacy supply chain
09/25/20 Deutsche Bank
Rite Aid price target lowered to $9 from $18 at Deutsche Bank
EOLS Evolus
$16.48 /

+0.38 (+2.36%)

03/24/21 H.C. Wainwright
Evolus price target raised to $20 from $18 at H.C. Wainwright
02/24/21 Truist
Evolus downgraded to Hold from Buy at Truist
02/24/21 Truist
Evolus downgraded to Hold from Buy at Truist
02/22/21 Barclays
Evolus price target raised to $8 from $4 at Barclays
KBH KB Home
$43.49 /

+0.12 (+0.28%)

03/16/21 Wolfe Research
KB Home initiated with an Outperform at Wolfe Research
02/19/21
Fly Intel: Top five analyst upgrades
02/19/21 Goldman Sachs
KB Home upgraded to Buy from Sell at Goldman Sachs
02/09/21
Fly Intel: Top five analyst downgrades
EVFM Evofem
$2.33 /

-0.245 (-9.53%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
FLL Full House Resorts
$6.70 /

-0.35 (-4.96%)

03/09/21 Macquarie
Full House Resorts price target raised to $10 from $8 at Macquarie
02/18/21 Union Gaming
Full House Resorts initiated with a Buy at Union Gaming
02/05/21 Macquarie
Full House Resorts price target raised to $8 from $6 at Macquarie
12/02/20 Macquarie
Full House Resorts price target raised to $5 from $4.50 at Macquarie
TCDA Tricida
$4.73 /

-0.29 (-5.78%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

KBH KB Home
$43.49 /

+0.12 (+0.28%)

JEF Jefferies Financial Group
$32.53 /

-0.34 (-1.03%)

FUL H.B. Fuller
$58.89 /

+0.68 (+1.17%)

FLL Full House Resorts
$6.70 /

-0.35 (-4.96%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

EOLS Evolus
$16.48 /

+0.38 (+2.36%)

  • 25
    Mar
  • 25
    Mar
  • 03
    Jun
EOLS Evolus
$16.48 /

+0.38 (+2.36%)

TCDA Tricida
$4.73 /

-0.29 (-5.78%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

KBH KB Home
$43.49 /

+0.12 (+0.28%)

JEF Jefferies Financial Group
$32.53 /

-0.34 (-1.03%)

FUL H.B. Fuller
$58.89 /

+0.68 (+1.17%)

FLL Full House Resorts
$6.70 /

-0.35 (-4.96%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

EOLS Evolus
$16.48 /

+0.38 (+2.36%)

RH RH
$486.00 /

-20.61 (-4.07%)

RAD Rite Aid
$23.33 /

-0.42 (-1.77%)

KBH KB Home
$43.49 /

+0.12 (+0.28%)

FLL Full House Resorts
$6.70 /

-0.35 (-4.96%)

EVFM Evofem
$2.33 /

-0.245 (-9.53%)

EOLS Evolus
$16.48 /

+0.38 (+2.36%)

Syndicate
Evofem files to sell $30M in common stock » 16:01
03/24/21
03/24
16:01
03/24/21
16:01
EVFM

Evofem

$2.35 /

-0.225 (-8.75%)

Morgan Stanley and Stifel…

Morgan Stanley and Stifel are acting as joint book-running managers for the proposed offering.

ShowHide Related Items >><<
EVFM Evofem
$2.35 /

-0.225 (-8.75%)

EVFM Evofem
$2.35 /

-0.225 (-8.75%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
EVFM Evofem
$2.35 /

-0.225 (-8.75%)

  • 03
    Jun
EVFM Evofem
$2.35 /

-0.225 (-8.75%)

EVFM Evofem
$2.35 /

-0.225 (-8.75%)

Hot Stocks
Evofem announces publication of manuscript from AMPREVENCE trial in AJOG » 08:07
03/16/21
03/16
08:07
03/16/21
08:07
EVFM

Evofem

$2.80 /

-0.045 (-1.58%)

Evofem Biosciences…

Evofem Biosciences announced publication of the pivotal manuscript from the AMPREVENCE clinical trial in the highly respected American Journal of Obstetrics and Gynecology. This double-blinded, placebo-controlled, multicenter study of EVO100 met its primary and secondary efficacy endpoints with statistically significant reductions in the risk of chlamydia and gonorrhea infections in women at high risk of infection. Building on the AMPREVENCE results, Evofem is currently enrolling EVOGUARD, its pivotal Phase 3 clinical trial of EVO100 for prevention of chlamydia and gonorrhea in women. The trial is on track to complete enrollment of the 1,730-subject cohort in 2021. Evofem expects to report top-line data in mid-2022. Positive EVOGUARD outcomes would support submission of a New Drug Application to the U.S. FDA for these potential indications by the end of 2022.

ShowHide Related Items >><<
EVFM Evofem
$2.80 /

-0.045 (-1.58%)

EVFM Evofem
$2.80 /

-0.045 (-1.58%)

03/08/21 H.C. Wainwright
Evofem price target lowered to $7 from $8 at H.C. Wainwright
10/01/20 Stifel
Evofem initiated with a Buy at Stifel
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
08/20/20 Morgan Stanley
Evofem initiated with an Equal Weight at Morgan Stanley
EVFM Evofem
$2.80 /

-0.045 (-1.58%)

  • 03
    Jun
EVFM Evofem
$2.80 /

-0.045 (-1.58%)

EVFM Evofem
$2.80 /

-0.045 (-1.58%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.